Maternal health, in-utero, and perinatal exposures and risk of thyroid cancer in offspring: a Nordic population-based nested case-control study.
Journal
The lancet. Diabetes & endocrinology
ISSN: 2213-8595
Titre abrégé: Lancet Diabetes Endocrinol
Pays: England
ID NLM: 101618821
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
13
05
2020
revised:
09
11
2020
accepted:
10
11
2020
pubmed:
22
12
2020
medline:
16
2
2021
entrez:
21
12
2020
Statut:
ppublish
Résumé
Thyroid cancer tends to be diagnosed at a younger age (median age 51 years) compared with most other malignancies (such as breast cancer [62 years] or lung cancer [71 years]). The incidence of thyroid cancer is higher in women than men diagnosed from early adolescence. However, few in-utero and early life risk exposures associated with increased risk of thyroid cancer have been identified. In this population-based nested case-control study we used registry data from four Nordic countries to assess thyroid cancer risk in offspring in relation to maternal medical history, pregnancy complications, and birth characteristics. Patient with thyroid cancer (cases) were individuals born and subsequently diagnosed with first primary thyroid cancer from 1973 to 2013 in Denmark, 1987 to 2014 in Finland, 1967 to 2015 in Norway, or 1973 to 2014 in Sweden. Each case was matched with up to ten individuals without thyroid cancer (controls) based on birth year, sex, country, and county of birth. Cases and matched controls with a previous diagnosis of any cancer, other than non-melanoma skin cancer, at the time of thyroid cancer diagnosis were excluded. Cases and matched controls had to reside in the country of birth at the time of thyroid cancer diagnosis. Conditional logistic regression models were used to calculate odds ratios (ORs) with 95% CIs. Of the 2437 cases, 1967 (81·4%) had papillary carcinomas, 1880 (77·1%) were women, and 1384 (56·7%) were diagnosed before age 30 years (range 0-48). Higher birth weight (OR per kg 1·14 [95% CI 1·05-1·23]) and congenital hypothyroidism (4·55 [1·58-13·08]); maternal diabetes before pregnancy (OR 1·69 [0·98-2·93]) and postpartum haemorrhage (OR 1·28 [1·06-1·55]); and (from registry data in Denmark) maternal hypothyroidism (18·12 [10·52-31·20]), hyperthyroidism (11·91 [6·77-20·94]), goiter (67·36 [39·89-113·76]), and benign thyroid neoplasms (22·50 [6·93-73·06]) were each associated with an increased risk of thyroid cancer in offspring. In-utero exposures, particularly those related to maternal thyroid disorders, might have a long-term influence on thyroid cancer risk in offspring. Intramural Research Program of the National Cancer Institute (National Institutes of Health).
Sections du résumé
BACKGROUND
Thyroid cancer tends to be diagnosed at a younger age (median age 51 years) compared with most other malignancies (such as breast cancer [62 years] or lung cancer [71 years]). The incidence of thyroid cancer is higher in women than men diagnosed from early adolescence. However, few in-utero and early life risk exposures associated with increased risk of thyroid cancer have been identified.
METHODS
In this population-based nested case-control study we used registry data from four Nordic countries to assess thyroid cancer risk in offspring in relation to maternal medical history, pregnancy complications, and birth characteristics. Patient with thyroid cancer (cases) were individuals born and subsequently diagnosed with first primary thyroid cancer from 1973 to 2013 in Denmark, 1987 to 2014 in Finland, 1967 to 2015 in Norway, or 1973 to 2014 in Sweden. Each case was matched with up to ten individuals without thyroid cancer (controls) based on birth year, sex, country, and county of birth. Cases and matched controls with a previous diagnosis of any cancer, other than non-melanoma skin cancer, at the time of thyroid cancer diagnosis were excluded. Cases and matched controls had to reside in the country of birth at the time of thyroid cancer diagnosis. Conditional logistic regression models were used to calculate odds ratios (ORs) with 95% CIs.
RESULTS
Of the 2437 cases, 1967 (81·4%) had papillary carcinomas, 1880 (77·1%) were women, and 1384 (56·7%) were diagnosed before age 30 years (range 0-48). Higher birth weight (OR per kg 1·14 [95% CI 1·05-1·23]) and congenital hypothyroidism (4·55 [1·58-13·08]); maternal diabetes before pregnancy (OR 1·69 [0·98-2·93]) and postpartum haemorrhage (OR 1·28 [1·06-1·55]); and (from registry data in Denmark) maternal hypothyroidism (18·12 [10·52-31·20]), hyperthyroidism (11·91 [6·77-20·94]), goiter (67·36 [39·89-113·76]), and benign thyroid neoplasms (22·50 [6·93-73·06]) were each associated with an increased risk of thyroid cancer in offspring.
INTERPRETATION
In-utero exposures, particularly those related to maternal thyroid disorders, might have a long-term influence on thyroid cancer risk in offspring.
FUNDING
Intramural Research Program of the National Cancer Institute (National Institutes of Health).
Identifiants
pubmed: 33347809
pii: S2213-8587(20)30399-5
doi: 10.1016/S2213-8587(20)30399-5
pmc: PMC7875310
mid: NIHMS1661273
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
94-105Subventions
Organisme : Intramural NIH HHS
ID : ZIA CP010219
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Thyroid. 2020 Oct 7;:
pubmed: 32912083
Cancer Epidemiol. 2019 Oct;62:101564
pubmed: 31325768
Environ Health Perspect. 2020 Sep;128(9):95002
pubmed: 32924579
BMC Cancer. 2015 May 13;15:398
pubmed: 25963309
Lancet Diabetes Endocrinol. 2020 Jun;8(6):468-470
pubmed: 32445733
Clin Epidemiol. 2019 Jul 12;11:563-591
pubmed: 31372058
Thyroid Res. 2015 Jun 18;8:8
pubmed: 26146517
Acta Obstet Gynecol Scand. 2014 Feb;93(2):132-7
pubmed: 24237585
Acta Oncol. 2018 Apr;57(4):440-455
pubmed: 29226751
J Clin Endocrinol Metab. 2018 Jun 1;103(6):2216-2224
pubmed: 29590402
Matern Child Nutr. 2021 Jan;17(1):e13050
pubmed: 32602197
Obstet Gynecol. 2011 Sep;118(3):561-568
pubmed: 21860284
J Intern Med. 2018 May;283(5):430-445
pubmed: 29476569
Cancer Res. 2014 Jan 1;74(1):235-42
pubmed: 24247722
Thyroid. 2017 Mar;27(3):315-389
pubmed: 28056690
Food Nutr Res. 2013 Apr 12;57:
pubmed: 23589711
Radiat Res. 1995 Mar;141(3):259-77
pubmed: 7871153
Cancer Causes Control. 2003 May;14(4):311-8
pubmed: 12846361
J Clin Endocrinol Metab. 2009 Feb;94(2):570-4
pubmed: 19017761
Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):976-85
pubmed: 24646451
Am J Epidemiol. 2003 Feb 1;157(3):258-66
pubmed: 12543626
Acta Obstet Gynecol Scand. 2000 Jun;79(6):440-9
pubmed: 10857867
Nat Rev Endocrinol. 2012 Nov;8(11):650-8
pubmed: 23007317
Horm Behav. 2004 Dec;46(5):663-9
pubmed: 15555509
Lancet Diabetes Endocrinol. 2015 Apr;3(4):286-95
pubmed: 25591468
J Clin Endocrinol Metab. 2019 Jan 1;104(1):41-48
pubmed: 30445441
J Clin Endocrinol Metab. 2013 Mar;98(3):965-72
pubmed: 23408571